Trails Edge Capital Partners, LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Trails Edge Capital Partners, LP reported 23 stock positions worth $404.7 million. Its top holding was Acadia Pharmaceuticals (ACAD) at 9.4% of the portfolio, followed by Mind Medicine Mindmed (8.5%) and Vaxcyte (PCVX, 8.4%).
- Most Recent 13F
- Q2 2026
- Location
- ATLANTA, GA
- CIK
- 0002077247
- Portfolio Value
- $404.7M (Q4 2025)
- SEC Filing
- 0002077247-26-000002 ↗ filed Feb 17, 2026
Holdings Value
Holdings 23 stocks · $404.7M
| ACAD Acadia Pharmaceuticals Inc. | 9.37% | 1,419,406 | $37.9M | — |
| MIND MEDICINE MINDMED INC | 8.50% | 2,568,110 | $34.4M | — |
| PCVX Vaxcyte Inc. | 8.41% | 737,470 | $34.0M | — |
| NRIX Nurix Therapeutics Inc. | 8.17% | 1,743,220 | $33.1M | — |
| LBRX LB Pharmaceuticals Inc. | 7.68% | 1,395,608 | $31.1M | — |
| XENE Xenon Pharmaceuticals Inc. | 6.61% | 597,092 | $26.8M | — |
| IMCR Immunocore Holdings PLC-ADR | 5.85% | 682,597 | $23.7M | — |
| RCUS Arcus Biosciences Inc. | 5.40% | 916,313 | $21.8M | — |
| TYRA Tyra Biosciences Inc. | 4.55% | 700,000 | $18.4M | — |
| NGNE Neurogene Inc. | 4.00% | 785,000 | $16.2M | — |
| FOLD Amicus Therapeutics Inc. | 3.67% | 1,043,313 | $14.9M | — |
| APGE Apogee Therapeutics Inc. | 3.58% | 192,000 | $14.5M | — |
| IKT Inhibikase Therapeutics Inc. | 3.13% | 6,178,124 | $12.7M | — |
| IVA Inventiva SA - ADR | 3.05% | 2,657,997 | $12.4M | — |
| CAMP CAMP4 Therapeutics Corp. | 3.00% | 1,983,986 | $12.2M | — |
| TERN Terns Pharmaceuticals Inc. | 2.99% | 300,000 | $12.1M | — |
| XFOR X4 Pharmaceuticals Inc. | 2.54% | 2,571,478 | $10.3M | — |
| MBX MBX Biosciences Inc. | 2.46% | 315,158 | $9.9M | — |
| VTVT VTV Therapeutics Inc. Class A | 2.28% | 231,000 | $9.2M | — |
| CMPX Compass Therapeutics Inc. | 1.88% | 1,415,273 | $7.6M | — |
| IMVT Immunovant Inc. | 1.51% | 240,165 | $6.1M | — |
| ELVN Enliven Therapeutics Inc. | 0.76% | 199,306 | $3.1M | — |
| MIRM Mirum Pharmaceuticals Inc. | 0.62% | 31,862 | $2.5M | — |
Portfolio Sells Q4 2025
No earlier filing to compare with.
Portfolio Buys Q4 2025
No earlier filing to compare with.